Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin, Ireland

ElizabethEstebana Dec. 7 at 3:55 AM

$XRP.X $FMCC $AMRN $CDTX $CVKD Trend favors the upside.

1 · Reply

CEVIN Dec. 7 at 2:17 AM

$AMRN So the SCOTUS blew up in our face and we find out tomorrow that we are not on the China approval list for 2026 because we never even applied….I see articles they were so slow they are looking at being included in the 2026 for possible approval starting 2027….Do hope I’m wrong otherwise this is a one trick pony heading to the Knacker’s Yard.

1 · Reply

SanDiegoLiving Dec. 7 at 1:55 AM

$AMRN Doesn't looks like they are going to announce them on this stream, its all policy speakers and discussion. From what some people are saying, it should be a couple hours afterwards when they finally post it to the main website. I'll keep an eye out for it, looks like we are waiting a little longer!

3 · Reply

SanDiegoLiving Dec. 7 at 1:09 AM

$AMRN Aight we live! Translating in chinese to english on the live stream. Took me FOREVER to get this to work right! 🤞🤞🤞

3 · Reply

thisguysfalling Dec. 7 at 12:18 AM

$AMRN I thought the NRDL news was supposed to have already been released?

1 · Reply

lillylang Dec. 6 at 11:55 PM

$AMRN

1 · Reply

declanaidan Dec. 6 at 10:48 PM

$AMRN So which will caprure most eyeballs tonight here at 8pm EST? NRDL release in China or #1 and #2 matchup of Ohio St v. Indiana on national TV?

2 · Reply

buygreensellredchop Dec. 6 at 8:19 PM

$AMRN please give us good news today.. 🤞

0 · Reply

jlucer53 Dec. 6 at 7:28 PM

$AMRN when is denner and management going to start giving guidance. This is pretty ridiculous at this point to stay radio silent on just about everything. It's fast frustrating. We get more insight from sdl than the company itself

1 · Reply

SanDiegoLiving Dec. 6 at 4:40 PM

$AMRN Got access to the Livestream later today for the NRDL release 🎯

7 · Reply

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 4 weeks ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Oct 29, 2025, 10:21 AM EDT - 5 weeks ago

Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 8:00 AM EDT - 7 weeks ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Sep 29, 2025, 5:52 PM EDT - 2 months ago

Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom

Aug 31, 2025, 8:30 AM EDT - 3 months ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 3 months ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 25, 2025, 8:00 AM EDT - 3 months ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Jul 30, 2025, 2:06 PM EDT - 4 months ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 4 months ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 4 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 5 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 7 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 7 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 7 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 8 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 8 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 8 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 9 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 9 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 9 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 10 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 10 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 4:13 PM EDT - 1 year ago

Why Amarin Stock Was Rocketing Higher on Wednesday

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

ElizabethEstebana Dec. 7 at 3:55 AM

$XRP.X $FMCC $AMRN $CDTX $CVKD Trend favors the upside.

1 · Reply

CEVIN Dec. 7 at 2:17 AM

1 · Reply

SanDiegoLiving Dec. 7 at 1:55 AM

3 · Reply

SanDiegoLiving Dec. 7 at 1:09 AM

$AMRN Aight we live! Translating in chinese to english on the live stream. Took me FOREVER to get this to work right! 🤞🤞🤞

3 · Reply

thisguysfalling Dec. 7 at 12:18 AM

$AMRN I thought the NRDL news was supposed to have already been released?

1 · Reply

lillylang Dec. 6 at 11:55 PM

$AMRN

1 · Reply

declanaidan Dec. 6 at 10:48 PM

$AMRN So which will caprure most eyeballs tonight here at 8pm EST? NRDL release in China or #1 and #2 matchup of Ohio St v. Indiana on national TV?

2 · Reply

buygreensellredchop Dec. 6 at 8:19 PM

$AMRN please give us good news today.. 🤞

0 · Reply

jlucer53 Dec. 6 at 7:28 PM

1 · Reply

SanDiegoLiving Dec. 6 at 4:40 PM

$AMRN Got access to the Livestream later today for the NRDL release 🎯

7 · Reply

SanDiegoLiving Dec. 6 at 3:47 PM

$AMRN 🚨 ANTITRUST LEGAL UPDATE | APOTEX CASE FACES DISMISSAL ON JANUARY 5TH ⚖️ The Apotex lawsuit is entering its defining moment. On January 5th the court will answer one question: "Does the Apotex complaint legally qualify as an antitrust case?" Amarin asked the judge to dismiss the case, and the suppliers Apotex named (KD Pharma) immediately joined that request. When every party aligns like this it usually means the legal theory is too weak to continue. 🤝🔍 What the judge does on January 5th: ✨ Treats every allegation as true only for this legal test 🎙️ Takes no testimony 📁 Allows no discovery 🧭 Issues one ruling that decides if the case lives or ends If the complaint fails this review, the case ends immediately with prejudice. 💥 A collapse also undercuts the related antitrust actions that rely on the same storyline. Once the core falls, the rest weaken and Amarin's longstanding legal antitrust overhang should begin to clear.

1 · Reply

soccerplayer06 Dec. 6 at 2:14 PM

$AMRN are we expecting a China approval before year end or what’s going on there?

1 · Reply

MoneyGroupLLC Dec. 6 at 7:13 AM

Enter: $AMRN Calls Strike Price: $17 Expiry Date: JAN 16 2026 Buy in Price: $1.25 - $1.95 Sell Price: $1.95 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Talleyville0311 Dec. 6 at 5:12 AM

$AMRN where’s the triangle man when you need him lol. Only the long time holders will remember who I’m talking about..

1 · Reply

studythosestocks Dec. 6 at 12:16 AM

$AMRN From Tasty the Elf “Folks, the Solicitor General has filed his Amicus Brief -- he thinks SCOTUS should take the case. Not great. https://www.supremecourt.gov/DocketPDF/24/24-889/386573/20251205145014514_24-889%20--%20Hikma%20Pharmaceuticals%20v.%20Amarin%20Pharma.pdf Recall of course that the Solicitor General also believed that SCOTUS should have taken GSK v Teva, and SCOTUS didn't.”

2 · Reply

CaptBeer Dec. 5 at 9:20 PM

BEER GOOD $AMRN GOOD.

0 · Reply

TraderRapp Dec. 5 at 9:02 PM

$AMRN half the average volume prior to big catalyst huh?

0 · Reply

declanaidan Dec. 5 at 8:37 PM

$AMRN I am jumping the gun on the Captain here, but gotta make an exit here for today. So Amarin good, beer good. And especially this weekend, Saturday night, we can be sitting around the campfire with some good Chinese brew?!

1 · Reply

MarvintheMOFO Dec. 5 at 7:44 PM

$AMRN Nearly 5 years ago my daughter was born and I was up 20k on $CLVS and then this Maffy POS stole all my money, still wishing death upon evil. The next few days, I have another one coming and this is my last big position, which is also negative, but being that life is a lifecycle, I see a 200% increasing coming in the next few weeks.

1 · Reply

smat732 Dec. 5 at 7:41 PM

$AMRN so… with China being 13 hours ahead of NYC… Saturday night or early Sunday am…

1 · Reply

smartinvest101 Dec. 5 at 6:26 PM

$AMRN I am surprised there is no leak yet. China is doing a good job keeping it air tight

0 · Reply

Freifaller Dec. 5 at 2:46 PM

$AMRN China’s 2026 National Reimbursement Drug List (NRDL) will be officially released on December 7, 2025, with changes taking effect January 1, 2026 "Release Date: December 7, 2025, in Guangzhou, followed by a detailed event in Beijing on December 9" https://www.navlindaily.com/article/28828/china-s-nrdl-commercial-catalog-scheduled-for-release-on-december-7

1 · Reply

Market Cap	343.92M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	51,500
Avg Vol	117,462
Day's Range	N/A - N/A
Shares Out	20.79M
Stochastic %K	91%
Beta	0.71
Analysts	Hold
Price Target	$12.00